# GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

> **NCT06875063** · PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 45 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma
- Refractory Lymphoma
- Chimeric Antigen Receptor T-cell

## Interventions

- **DRUG:** GB5005 CART

## Key facts

- **NCT ID:** NCT06875063
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06875063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06875063, "GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06875063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*